Clover Biopharmaceuticals Ltd. Statistics
Want to see HK:2197 full AI Analyst Report?
Clover Biopharmaceuticals Ltd. (2197) Stock Statistics & Valuation Metrics
Total Valuation
Clover Biopharmaceuticals Ltd. has a market cap or net worth of HKD 2.16B. The enterprise value is HKD 1.97B.
- Market Cap
- HKD 2.16B
- Enterprise Value
- HKD 1.97B
Share Statistics
Clover Biopharmaceuticals Ltd. has 1,298,789,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,298,789,900
- Owned by Insiders
- ―
- Owned by Institutions
- 0.47%
Financial Efficiency
Clover Biopharmaceuticals Ltd.’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 19.48%.
- Return on Equity (ROE)
- 0.11
- Return on Assets (ROA)
- -0.44
- Return on Invested Capital (ROIC)
- 19.48%
- Return on Capital Employed (ROCE)
- 0.19
- Revenue Per Employee
- 13.29K
- Profits Per Employee
- -777.37K
- Employee Count
- 257
- Asset Turnover
- 0.01
- Inventory Turnover
- 2.76
Valuation Ratios
The current PE Ratio of Clover Biopharmaceuticals Ltd. is 2.15. Clover Biopharmaceuticals Ltd.’s PEG ratio is 0.00.
- PE Ratio
- 2.15
- PS Ratio
- 4347.22
- PB Ratio
- -2.24
- Price to FCF
- -7.07
- Price to Operating Cash Flow
- -6.89
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Clover Biopharmaceuticals Ltd. had revenue of 3.41M and earned -199.78M in profits. Earnings per share was -0.16.
- Revenue
- 3.41M
- Gross Profit
- -23.85M
- Operating Income
- -247.75M
- Pretax Income
- -199.78M
- Net Income
- -199.78M
- EBITDA
- -221.24M
- Earnings Per Share (EPS)
- -0.16
Cash Flow
In the last 12 months, operating cash flow was -260.44M and capital expenditures -614, giving a free cash flow of -260.44M billion.
- Operating Cash Flow
- -260.44M
- Free Cash Flow
- -260.44M
- Free Cash Flow per Share
- -0.21
Dividends & Yields
Clover Biopharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.19%
- Earnings Yield
- 47.11%
Stock Price Statistics
- Beta
- 1.73
- 52-Week Price Change
- -38.56%
- 50-Day Moving Average
- 1.71
- 200-Day Moving Average
- 2.09
- Relative Strength Index (RSI)
- 58.54
- Average Volume (3m)
- 3.26M
Important Dates
Clover Biopharmaceuticals Ltd. upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 25, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
Clover Biopharmaceuticals Ltd. as a current ratio of 0.19, with Debt / Equity ratio of -0.59%
- Current Ratio
- 0.19
- Quick Ratio
- 0.19
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.18
- Interest Coverage Ratio
- -674.64
Taxes
In the past 12 months, Clover Biopharmaceuticals Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Clover Biopharmaceuticals Ltd. EV to EBITDA ratio is -6.97, with an EV/FCF ratio of -6.71.
- EV to Sales
- 4126.15
- EV to EBITDA
- -6.97
- EV to Free Cash Flow
- -6.71
- EV to Operating Cash Flow
- -6.71
Balance Sheet
Clover Biopharmaceuticals Ltd. has HKD 104.77M in cash and marketable securities with HKD 2.08M in debt, giving a net cash position of HKD 102.68M billion.
- Cash & Marketable Securities
- HKD 104.77M
- Total Debt
- HKD 2.08M
- Net Cash
- HKD 102.68M
- Net Cash Per Share
- HKD 0.08
- Tangible Book Value Per Share
- -HKD 0.65
Margins
Gross margin is -9099.11%, with operating margin of -64902.56%, and net profit margin of 199197.33%.
- Gross Margin
- -9099.11%
- Operating Margin
- -64902.56%
- Pretax Margin
- 198352.64%
- Net Profit Margin
- 199197.33%
- EBITDA Margin
- -59215.47%
- EBIT Margin
- -64902.56%
Analyst Forecast
The average price target for Clover Biopharmaceuticals Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -99.15%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 5
- AI Score
- 45

